Effects of Streptococcus salivarius K12 with nystatin on oral candidiasis-RCT.
Lijun HuQinghua MaoPeiru ZhouXin LvHong HuaZhimin YanPublished in: Oral diseases (2019)
Streptococcus salivarius K12 exhibited potential efficacy and safety as an adjuvant in treating oral candidiasis by enhancing mycological cure and shortening the treatment course of conventional antifungal therapy in this randomized, double-blinded, placebo-controlled clinical trial. Further large-scale clinical studies are desired to accumulate more evidence for its clinical applications.
Keyphrases
- candida albicans
- double blind
- placebo controlled
- clinical trial
- biofilm formation
- phase ii
- phase iii
- open label
- study protocol
- phase ii study
- randomized controlled trial
- radiation therapy
- risk assessment
- pseudomonas aeruginosa
- squamous cell carcinoma
- human health
- climate change
- staphylococcus aureus
- escherichia coli
- bone marrow
- locally advanced
- replacement therapy